GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data became available.In June, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.
六月份，美國疾病控制和預防中心（CDC）的免疫接種實踐諮詢委員會（ACIP）投票建議所有年齡在75歲及以上的成年人定期接種呼吸道合胞病毒（RSV）疫苗。
The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions.
該專家組還建議對60至74歲，處於嚴重RSV疾病增高風險的成年人進行RSV免疫接種，即因具有某些慢性醫療狀況。
The recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine.
建議針對去年未接種RSV疫苗的成年人。RSV疫苗目前不是一項年度疫苗。
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data became available.
ACIP推遲對於處於50至59歲且處於增高RSV-下呼吸道界定疾病風險的成人的免疫接種建議的表決，直到有更多數據可用。
U.S. sales of RSV vaccines from GSK Plc (NYSE:GSK) and Pfizer Inc (NYSE:PFE) have declined after regulators narrowed the age group eligible for the shots and determined they would be a one-time vaccination for now.
在監管機構限制符合接種條件的年齡群體並確定目前只能是一次性疫苗之後，輝瑞公司（NYSE:PFE）和GSK Plc（紐交所：GSK）的RSV疫苗在美國的銷售額有所下降。
This change excluded millions who were vaccinated last year, impacting demand.
此變化排除了去年接種的成百萬人，對需求產生了影響。
Pharmacists report that the demand for RSV vaccines has dropped by up to two-thirds compared to last year. Reuters highlights that data from healthcare analytics company IQVIA Holdings, Inc (NYSE:IQV) supports these claims.
藥劑師報告稱，與去年相比，對RSV疫苗的需求下降了三分之二。路透社強調，來自保健分析公司IQVIA Holdings, Inc（紐交所：IQV）的數據支持這些說法。
For Pfizer and GSK, RSV vaccines are critical as they seek to build new revenue streams before facing generic competition for their top-selling drugs.
對於輝瑞和GSK來說，RSV疫苗至關重要，因爲他們希望在他們的暢銷藥面臨仿製競爭之前建立新的營業收入渠道。
Pfizer is already struggling with weak demand for its COVID-19 products and pressure from activist investor Starboard Value.
輝瑞已經面臨COVID-19產品需求疲軟和來自激進投資者Starboard Value的壓力。
Despite a disappointing launch for its RSV vaccine Abrysvo in 2023, Reuters notes that CEO Albert Bourla remains optimistic about its potential in the U.S. market this year.
路透社指出，儘管2023年Abrysvo RSV生物-疫苗的推出令人失望，CEO阿爾伯特·鮑拉仍對該產品在美國市場的潛力持樂觀態度。
In 2023, an average of 440,000 people per week received RSV vaccines from GSK and Pfizer in September, with 65% opting for GSK's Arexvy. However, this September, the weekly average fell to 157,000.
2023年9月，平均每週有44萬人接種了GSK和輝瑞的RSV疫苗，其中65%選擇了GSK的Arexvy。然而，今年9月，每週平均接種人數下降至157,000人。
Pharmacists in Nebraska and Iowa have seen bookings drop by 65% compared to last year, while Pharmacy in New York reported an even steeper decline.
內布拉斯加州和愛荷華州的藥劑師看到預訂量比去年下降了65%，而紐約的藥房甚至報告了更爲嚴重的下降。
On Tuesday, GSK announced new data from the AReSVi-006 phase 3 trial of a single dose of Arexvy in adults aged 60 years and older, including those at increased risk, over three full RSV seasons.
週二，GSK宣佈了AReSVi-006第3期試驗的新數據，該試驗包括對60歲及以上成年人以及處於增加風險中的人在三個完整的RSV季節中使用Arexvy單劑量的試驗結果。
Results indicate that after a single dose of GSK's RSV vaccine, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD compared to placebo.
結果表明，在接種一劑GSK的RSV疫苗後，在三個完整的RSV季節中，對RSV-LRTD的累積有效性爲62.9%，對嚴重RSV-LRTD的有效性爲67.4%，相對於安慰劑具有臨床意義。
In the third season, the vaccine's efficacy was 48.0% against RSV-LRTD. These results include efficacy against different RSV subtypes in adults with advancing age (70-79 years) and those with certain underlying medical conditions.
在第三個季節，該疫苗對RSV-LRTD的有效性爲48.0%。這些結果包括針對不同RSV亞型的有效性，以及針對年齡增長（70-79歲）和特定基礎醫療條件的成年人。
- United Airlines Takes Flight With Global Expansion: New Routes To Spain, Italy, And More
- 聯合大陸航空展開全球擴張：新增前往西班牙、意大利等國的航線
Image via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
